HealthCare Global Enterprises Limited has approved the divestment of its entire equity shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I and its nominee. The Board of Directors and Audit Committee granted approval during meetings held on May 19, 2026. The transaction is valued at INR 37,64,44,788 and is expected to be completed within 4-5 weeks from the date of the announcement, subject to the terms of the Share Purchase Agreement (SPA). BACC is engaged in fertility and reproductive healthcare services, which the company identified as a non-core business activity.

Transaction Details

The proposed transaction is a related party transaction, as the buyer, Inviga Healthcare Fund I, is controlled by Dr. B.S. Ajaikumar, the Promoter and Non-Executive Chairman of the company. The deal was approved following a competitive process. The company stated that the transaction is being undertaken on an arm's length basis, with the consideration based on a valuation report by an independent third-party valuer.

Financial Impact of BACC

For the financial year 2025-26, BACC reported revenue from operations of INR 60.45 crore, which accounted for 4.45% of the company's standalone revenue. The net worth of BACC as of March 31, 2026, stood at INR 17.53 crore, representing 1.09% of the company's standalone net worth. The divestment is expected to facilitate greater operational focus, allowing the company to reinvest capital in high-growth areas such as cancer services.

BACC Financial Metrics (FY 2025-26)

The following table summarises BACC's key financial metrics relative to HCG's standalone figures:

Payment Structure

The consideration of INR 37,64,44,788 will be paid in two tranches. An aggregate amount of INR 28,23,33,591 is payable on the date of closing. The remaining deferred consideration of INR 9,41,11,197 will be paid within 18 months of the signing of the SPA.

HealthCare Global Enterprises Limited has announced a series of key appointments and re-appointments following its Board meeting held on May 19, 2026. The decisions, taken under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, include changes to the Board of Directors, the Chief Financial Officer, and senior management personnel.

Board and Senior Management Changes

The Board approved the re-appointment of Mr. Rajiv Maliwal as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 25, 2026. This re-appointment is subject to the approval of the company's shareholders. Mr. Maliwal shall not be liable to retire by rotation.

In a significant shift in the finance leadership, Mr. Sanjeev Kumar has been appointed as the Chief Financial Officer and Key Managerial Personnel of the company. His appointment is effective from the commencement of business hours on May 25, 2026. Consequently, Dr. Manish Mattoo, who was serving as the Interim Chief Financial Officer, shall cease to hold this position effective from the same date.

New Investor Relations Head

The company has strengthened its investor relations function with the appointment of Mr. Ravi Gothwal as AVP – Investor Relations. He has been designated as a Senior Management Personnel, with his appointment effective immediately from May 19, 2026.

Internal Auditor Re-appointment

The Board also approved the re-appointment of Mr. Vijay S. Shanbhag as the Internal Auditor of the company for a further term of one year. This appointment under Section 138 of the Companies Act, 2013, is effective from May 30, 2026.

Summary of Appointments